CERN Successfully Tests LFS-3 Plates

Zecotek’s LFS-3 Scintillation Crystal Plates Successfully Tested for Final Qualification for Hadron Collider Experiments at CERN

Singapore, December 1, 2014Zecotek Photonics Inc. (TSX-V: ZMS; Frankfurt: W1I.F), a developer of leading-edge photonics technologies for industrial, healthcare and scientific markets, today announced that the previously announced new configuration of LFS scintillation crystals (LFS-3 plates) have been successfully assessed by CERN scientists of the Large Hadron Collider using the high energy beam upgrade. Due to the positive results, the scientific team at CERN has ordered additional LFS-3 plates to be integrated into modules for the main Compact Muon Solenoid (CMS) experiment. The Company was informed by the CERN group that the details of a qualification contract and supply agreement will be finalized in early 2015.

“We are excited about the progress taking place at CERN and look forward to the opportunity to have our newly configured LFS technology used in CERN`s upgrade Large Hadron Collider,” said Dr. A.F. Zerrouk, Chairman, President, and CEO of Zecotek Photonics Inc. “Our new LFS plates with their new design, unique and unmatched cost performance advantages fulfill the principle criteria necessary for higher energies to be generated in the new LHC upgrades and CMS experiments. We are working with our strategic partner BOET and other associates to finalize the logistic and economic requirements to meet the contractual requirements anticipated in early 2015.”

The CMS Experiment is one of two large general-purpose particle physics detectors built on the Large Hadron Collider at CERN in Europe. It is composed of three main components: scintillation material, photo-detectors and the ubiquitous electronic system. Zecotek’s new LFS-3 plates were originally tested for use in CERN`s high energy experiments because of their density of material, stopping power, fast decay time, very good energy resolution, unique radiation hardness, and competitive effective price.

In March 2013, CERN scientists confirmed that a new subatomic particle discovered at the world’s most powerful particle accelerator is the Higgs Boson. As CERN pushes into this new frontier of science, additional experiments are required to determine the particle’s properties and its true form. High-energy scintillation crystals with high radiation hardness and solid-state photo detectors are paramount for the success of the next stage of experiments.

-30-

About the CMS Experiment at CERN
CMS is one of two general-purpose experiments at CERN’s Large Hadron Collider (LHC) that have been built to search for new physics. CMS is designed to detect a wide range of particles and phenomena produced in the LHC’s high-energy proton-proton and heavy-ion collisions. At CMS, scientists are looking into the unknown and trying to answer the most fundamental questions about our Universe, for example: “What is the Universe really made of and what forces act within it?” and “What gives everything substance?”. CMS also measures the properties of well-known particles with unprecedented precision and is on the lookout for completely new, unpredicted phenomena. Such research not only increases our understanding but may eventually spark new technologies that could change the world we live in. The CMS experiment is one of the largest international scientific collaborations in history, involving 4300 particle physicists, engineers, technicians, students and support staff from 179 universities and institutes in 41 countries. For more information about CMS please visit http://cms.web.cern.ch.

About Zecotek
Zecotek Photonics Inc (TSX-V: ZMS; Frankfurt: W1I) is a photonics technology company developing high-performance scintillation crystals, photo detectors, positron emission tomography scanning technologies, 3D auto-stereoscopic displays, and lasers for applications in medical, high-tech and industrial sectors. Founded in 2004, Zecotek operates three divisions: Imaging Systems, Laser Systems and 3D Display Systems with labs located in Canada, Korea, Russia, Singapore and U.S.A. The management team is focused on building shareholder value by commercializing over 50 patented and patent pending novel photonic technologies directly and through strategic alliances and joint ventures with leading industry partners such as Hamamatsu Photonics (Japan), the European Organization for Nuclear Research (Switzerland), Beijing Opto-Electronics Technology Co. Ltd. (China), NuCare Medical Systems (South Korea), and National NanoFab Center (South Korea). For more information visit Zecotek Photonics, follow @zecotek on Twitter.

This press release may contain forward-looking statements that are based on management’s expectations, estimates, projections and assumptions. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what may have been stated.

For Additional Information Please Contact:

Michael Minder
Zecotek Photonics Inc.
Unit 1120 – 21331 Gordon Way
Richmond, BC V6W 1J9
T: (604) 783-8291
ir@zecotek.com

The TSX Venture 50® are the top 10 companies listed on the TSX Venture Exchange, in each of five major industry sectors – mining, oil & gas, technology & life sciences, diversified industries and clean technology – based on a ranking formula with equal weighting given to return on investment, market cap growth, trading volume and analyst coverage. All data was as of December 31, 2013.

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the content of this news release. If you would like to receive news from Zecotek in the future please visit the corporate website at www.zecotek.com.

print